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Mandy Jayne Peffers1*, Yongxiang Fang2, Kathleen Cheung3, Tim Koh Jia Wei4, Peter David Clegg1
and Helen Lucy Birch5Abstract
Introduction: The risk of tendon injury and disease increases significantly with increasing age. The aim of the study
was to characterise transcriptional changes in human Achilles tendon during the ageing process in order to identify
molecular signatures that might contribute to age-related degeneration.
Methods: RNA for gene expression analysis using RNA-Seq and quantitative real-time polymerase chain reaction
analysis was isolated from young and old macroscopically normal human Achilles tendon. RNA sequence libraries
were prepared following ribosomal RNA depletion, and sequencing was undertaken by using the Illumina HiSeq
2000 platform. Expression levels among genes were compared by using fragments per kilobase of exon per million
fragments mapped. Differentially expressed genes were defined by using Benjamini-Hochberg false discovery rate
approach (P <0.05, expression ratios 1.4 log2 fold change). Alternative splicing of exon variants were also examined
by using Cufflinks. The functional significance of genes that showed differential expression between young and old
tendon was determined by using ingenuity pathway analysis.
Results: In total, the expression of 325 transcribed elements, including protein-coding transcripts and non-coding
transcripts (small non-coding RNAs, pseudogenes, long non-coding RNAs and a single microRNA), was significantly
different in old compared with young tendon (±1.4 log2 fold change, P <0.05). Of these, 191 were at higher levels
in older tendon and 134 were at lower levels in older tendon. The top networks for genes differentially expressed
with tendon age were from cellular function, cellular growth, and cellular cycling pathways. Notable differential
transcriptome changes were also observed in alternative splicing patterns. Several of the top gene ontology terms
identified in downregulated isoforms in old tendon related to collagen and post-translational modification of
collagen.
Conclusions: This study demonstrates dynamic alterations in RNA with age at numerous genomic levels, indicating
changes in the regulation of transcriptional networks. The results suggest that ageing is not primarily associated
with loss of ability to synthesise matrix proteins and matrix-degrading enzymes. In addition, we have identified
non-coding RNA genes and differentially expressed transcript isoforms of known matrix components with ageing
which require further investigation.Introduction
The increasing number of people reaching old age pro-
vides huge challenges to society, as whereas life span in-
creases, life quality faced by many individuals in old age
is poor [1]. Whereas muscle, bone, and joint age-related
disease is well recognised, the fibrous connecting tendon* Correspondence: peffs@liv.ac.uk
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very common site of pain and dysfunction. Epidemio-
logical studies have revealed a clear link between age
and increasing incidence of tendon injury [2,3], suggest-
ing that the mechanical integrity of tendon declines dur-
ing the ageing process.
Although it is generally accepted that a degenerative
process precedes gross tendon injury, the aetiology of
this process remains elusive and the definition of de-
generation is poorly defined. Histological examination of
painful Achilles tendon [4], dysfunctional posterior tibialisThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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has revealed pathological changes, including signs of colla-
gen fibre disruption, increased staining for glycosamino-
glycan, hypercellularity, and cell shape change to a more
chondroid appearance. Similar changes have been ob-
served in macroscopically abnormal equine flexor tendon
[7], another common site of age-associated tendon injury.
Histological abnormalities are more often observed in
older individuals [6], although the relationship with ageing
and the apparent change in cell function is not clear.
Ageing is generally associated with a decline in protein
synthesis [8] and a loss of cell functionality [9]. It has been
suggested that early degenerative changes in tendon result
from an accumulation of micro-damage within the extra-
cellular matrix (ECM) due to an imbalance between ana-
bolic and catabolic pathways [10]. Recent work on equine
flexor tendon identified an accumulation of partially de-
graded collagen within the ECM of old tendons, and it
was hypothesised that an inability to remove partially de-
graded collagen may account for reduced mechanical
competency [11]. Another study found that flexor tendon
explants from older horses were more susceptible to fa-
tigue damage following cyclical loading in vitro than
explants from young horses and that this was a cell-
mediated process involving the matrix metallo-proteinases
(MMPs) [12].
Cell ageing has been associated with a decreased ability
to modulate inflammation resulting in a chronic low-level
inflammation termed ‘inflamm-aging’ [13]. Recent work
by Dakin and colleagues [14] measured prostaglandin E2
in injured equine flexor tendons and found that levels in-
creased with increasing horse age but that levels of formyl
peptide receptor 2/ALX, a receptor responsible for sup-
pressing the inflammatory response, were significantly re-
duced. These findings intimate that aged individuals
exhibit a reduced capacity to resolve inflammation and
that ageing may contribute to deregulated tendon repair
through these pathways.
Quantitative analysis of gene expression changes with
age may help the understanding of ageing mechanisms
and their interactions with age-related diseases such as
tendinopathies [15]. Although microarray technology has
been employed to investigate gene expression changes fol-
lowing tendon injury [16], in tendinopathic tissue [17], in
response to cyclical strain [18] or a single loading event
[19], and effect of loading on tendon healing [20], no com-
prehensive analysis of alterations in gene expression with
age has been undertaken in tendon.
RNA-Seq can capture the whole transcriptome, includ-
ing coding RNAs, isoforms produced by alternative spli-
cing, long non-coding RNAs (lncRNAs) (the importance
of which is becoming apparent in disease [21] and age-
ing [22-24]), and short non-coding RNAs. We have pre-
viously used RNA-Seq successfully on equine cartilagetissue and identified an over-representation of genes with
reduced expression relating to ECM, degradative prote-
ases, matrix synthetic enzymes, cytokines, and growth fac-
tors in ageing cartilage [24].
In this study, we used RNA-Seq to comprehensively
identify the human Achilles tendon transcriptome for the
first time and then examine changes that occur with age-
ing. We hypothesised that ageing results in reduced ex-
pression of ECM-related proteins and matrix-degrading
enzymes. In addition, we sought to identify previously un-
recognised slice variants and non-coding RNAs associated
with tendon ageing in a ‘bottom-up’ inductive approach.
Methods
Sample collection and preparation
All human Achilles tendons used in this study—RNA-Seq
and quantitative real-time polymerase chain reaction
(qRT-PCR)—were harvested from limbs amputated during
surgical procedures to treat sarcomas at the Royal National
Orthopaedic Hospital, Stanmore. Tissue collection was
carried out through the Stanmore Musculoskeletal Bio-
Bank, which has ethical approval from the Cambridgeshire
1 Research Ethics Committee (REC reference 09/H0304/
78) to collect tissue for research into musculoskeletal con-
ditions. All patients gave consent for their tissue to be used
for musculoskeleton-related research. Local research-and-
development approval for this project was given by the
UCL/UCLH/RF Joint Research Office (reference number
11/0464). For RNA-Seq, tendons were collected from do-
nors who were 69.4 ± 7.3 years old (old group, n = 5, 3 fe-
male, 2 male) and donors who were 19 ± 5.8 years old
(young group, n = 4, 4 male). Tendon tissue was collected
within 24 hours of limb removal, except for one sample in
which tissue was collected within 48 hours. The Achilles
tendon was dissected free from the limb. Only tendons
with a normal macroscopic appearance were used for this
study. A section of tissue approximately 1 cm in length
was taken from the mid region of the tendon between the
musculotendinous junction and the insertion site. Outer
tissue (paratenon) was removed and the remaining tendon
tissue placed into RNAlater (Ambion, Warrington, UK) in
accordance with the instructions of the manufacturer.
RNA extraction
Tendon was pulverising into a powder with a dismem-
branator (Mikro-S; Sartorius, Melsungen, Germany)
following freezing in liquid nitrogen. Immediately, 20
volumes of Tri Reagent (Ambion) was added to the
powdered tendon tissue and the RNA extracted and
purified as described by Peffers et al. [25] (2013). RNA
was quantified by using a Nanodrop ND-100 spectro-
photometer (Labtech, Uckfield, East Sussex, UK) and
assessed for purity by UV absorbance measurements at
260 and 280 nm.
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Total RNA was analysed by the Centre for Genomic Re-
search, University of Liverpool, for RNA-Seq library prep-
aration and sequencing by using the Illumina HiSeq 2000
platform. Total RNA integrity was confirmed by using an
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA). Ribosomal RNA (rRNA) was depleted
from 9 total RNA samples by using the Ribo-Zero™ rRNA
Removal Kit (Human/Mouse/Rat; Epicentre, Madison,
WI, USA) in accordance with the instructions of the
manufacturer. cDNA libraries were prepared with the
ScriptSeq v2 RNA-Seq library preparation kit (Epicentre)
by using 50 ng rRNA depleted RNA as starting material in
accordance with manufacturer protocols as previously de-
scribed [24]. The final pooled library was diluted to 8 pmol
before hybridisation. The dilute library (120 μL) was hybri-
dised on one lane of the HiSeq 2000 at 2 × 100-base pair
(bp) paired-end sequencing with v3 chemistry.
Data processing
The sequence libraries for each sample were processed by
using CASAVA version 1.8.2 to produce 100-bp paired-end
sequence data in fastq format. The fastq files were proc-
essed by using Cutadapt version 1.2.1 [26] with option ‘–O
3’ to trim adapter from any read if it matched the adapter
sequence for 3 bp or more at the 3′ end. In addition, a qual-
ity trimming was performed by using Sickle version 1.200.
The trimmed R1-R2 read pairs, for each sample, were
aligned to reference sequence [27] by using TopHat2
version 2.0.10 [28] with default settings, except for the
option –g 1. Read counts were obtained from the mapping
results by using HTSeq-count and genome annotation [29].
The differential gene expression analysis was performed
on R platform by using the edgeR package [30] and fo-
cused on the contrast of old and young donors. The count
data were normalised across libraries by using trimmed
mean M (TMM) values of the default methods edgeR.
The tagwise dispersions were estimated and then used for
logFC (log2 fold change) estimating and testing. Differen-
tially expressed genes (DEGs) were extracted by applying
the threshold false discovery rate (FDR) of less than 0.05
to adjusted P values, which were generated by using Ben-
jamini and Hochberg approach [31]. In addition, FPKM
(fragments per kilobase of exon per million fragments
mapped) values were converted from count values for
comparing expression levels among genes. All sequence
data produced in this study have been submitted to
National Center for Biotechnology Information Gene
Expression Omnibus (NCBI GEO) under Array Express
accession number E-MTAB-2449.
Analysis of splice variants
Trimmed paired reads were aligned to a reference human
transcriptome (Ensembl iGenomes build GRCh37) byusing Bowtie2 [32]. The alignments (BAM files) were
converted into sorted SAM files by using SAMtools [33].
Parameters for TopHat were estimated by using a Picard
tool (CollectInsertSizeMetrics.jar) [34]. Reads were aligned
to the reference genome (Ensembl build GRCh37) by using
TopHat [35], specifying mate inner distance (mean inner
distance between mate pairs) and standard deviation for
each sample. Mapped reads were then assembled into
complete transcripts by using the splice junction mapping
tool Cufflinks [36] with option –G, which uses the Ensembl
reference gene track to improve mapping. Cuffmerge was
used to merge the assembled transcripts into a consensus
gene track from the all of the mapped samples. Cuffdiff
was used to identify DEGs and differentially expressed
transcripts between young and old tendon. Genes and
transcripts were identified as being significantly differen-
tially expressed with q values of less than 0.05, calculated
by the Benjamini and Hochberg FDR correction [31].
Downstream analysis and visualisation of results, includ-
ing quality control of the samples, was undertaken by
using the cummeRbund package in R. Graphs were gener-
ated by using cummeRbund and the ggplot2 package [37].
Functional analysis
To systematically determine networks, functional ana-
lyses, and canonical pathways that the DEGs might in-
volve, we performed the pathway/network enrichment
analysis using the ingenuity pathway analysis (IPA) tool
from the Ingenuity Systems [38] by using a list of DEGs
with values-adjusted P value of less than 0.05 and ±1.4
log2 fold regulation. Gene symbols were used as identi-
fiers and the Ingenuity Knowledge Base gene was used
as a reference for a pathway analysis. For network ge-
neration, a data set containing gene identifiers and cor-
responding expression values was uploaded. Default
settings were used to identify molecules whose expres-
sion was significantly differentially regulated. These mol-
ecules were overlaid onto a global molecular network
contained in the Ingenuity Knowledge Base. Networks of
‘network-eligible molecules’ were then algorithmically
generated based on their connectivity. The functional
analysis identified the biological functions and diseases
that were most significant to the data set. Right‐tailed
Fisher’s exact test was used to calculate P values. Canonical
pathways analysis identified the pathways from the IPA li-
brary that were most significant to the data set.
For isoform analysis, the Database for Annotation,
Visualization and Integrated Discovery (DAVID) (DA-
VID bioinformatics resources 6.7) was used [39]. The
web-based functional annotation tool enabled functional
clustering of gene. The functional clustering tool was
used for functional enrichment for DEG isoforms with
values-adjusted P value of less than 0.05 and ±1.4 log2
fold regulation.
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Samples of RNA from both the same pools used for the
RNA-Seq analysis and an additional independent cohort
harvested in the same manner (n = 4 young; 16.7 ±
2.8 years old and n = 4 old; 73.2 ± 6.5 years old) were
used for qRT-PCR. To validate results from differentially
expressed isoforms, the independent cohort was used.
Moloney murine leukaemia virus (M-MLV) reverse tran-
scriptase and random hexamer oligonucleotides (both
from Promega, Southampton, UK) were used to synthesize
cDNA from 1 μg RNA in a 25 μL reaction. PCR was per-
formed on 1 μL 10× diluted cDNA by employing a final
concentration of 300 nM of each primer in 20 μL reaction
volumes on an ABI 7700 Sequence Detector using Primer-
Design 2X PrecisionTM SYBR Green Mastermix (Primer
Design, Southampton, UK). qRT-PCR was undertaken by
using gene-specific primers (for protein-coding genes
these were exon-spanning). Primers used had been vali-
dated in previous publications [40,41] and supplied by
Eurogentec (Seraing, Belgium) or were designed and vali-
dated commercially (Primer Design). Steady-state tran-
script abundance of potential endogenous control
genes was measured in the RNA-Seq data. Assays for
four genes—glucose-6-phosphate isomerise (GPI), beta-
actin (ACTB), ribosomal protein 13 (RSP13), and ribo-
somal protein 16 (RPS16)—were selected as potential
reference genes as their expression was unaltered. Stability
of this panel of genes was assessed by applying a gene sta-
bility algorithm [42]. RSP16 was selected as the most
stable endogenous control gene. Relative expression levels
were normalised to RPS16 and calculated by using the
2−ΔCt method [43]. Primers pairs used in this study are
listed (Table 1). qRT-PCR analysis data was log10-
transformed to ensure normal distribution and then ana-
lysed by using Student’s t test.
Statistical analysis
The analyses were undertaken by using edgeR [30], S-Plus
(version 7.0; Tibco Software Inc., Palo Alto, CA, USA),
SPSS (version 20; IBM, Portsmouth, Hampshire, UK), and
Excel (2007; Microsoft, Redmond, WA, USA) software.
Results
Overview of RNA-Seq data
An average of 32.1 million pairs of 100-bp paired-end
reads per sample were generated that aligned to the ref-
erence sequence of the human genome. Using pooled R1
and R2 files for all samples in Trimmed data gave 95.1%
of called bases with of Phred score of more than 30 [44].
(See Table 2 for summary of mapping results.) Of the
63,152 human genes, between 40.5% and 47.4% had at
least one read aligned; 20,322 of the genes had no reads
aligned from any of the nine samples. This is similar to
the output of other RNA-Seq sequencing studies [24,45].These reads were used to estimate transcript expres-
sion of all nine samples using FPKM in order to identify
the most abundant genes in tendon. Table 3 demon-
strates the 25 most highly expressed genes in young and
old tendon (the entire data set is in Additional file 1).
Identification of differentially expressed genes and
isoforms
A principal component analysis (PCA) plot of log2 gene
expression data indicated that the effect of age on gene ex-
pression was distinct as data were clustered in two groups
(Figure 1A). Within the young group, two samples
clustered together and two were independent of each other
indicating more variability between young donors. Alter-
ations in gene expression between young and old tendon
demonstrated significant age-related changes. In total, the
expression of 325 transcribed elements, including protein-
coding transcripts and non-coding transcripts, small non-
coding RNAs (snoRNAs), pseudogenes, lncRNAs, and a
single microRNA, was significantly different in old com-
pared with young tendon (±1.4 log2 fold change, FDR-
adjusted P value of less than 0.05) (Figure 1B). Of these,
191 were at higher levels in the older tendon and 134 were
at lower levels in the older tendon. The top 10 genes most
DEG (increased and decreased) during tendon ageing are
given in Table 4. The entire list of significantly DEG tran-
scripts is presented in Additional file 2. NCBI GEO under
accession number E-MTAB-2449 contains a complete list
of all genes mapped. Of the 191 transcripts expressed at a
higher level in old donors, 148 were known protein-coding
genes. The remaining 43 genes contained 34 lncRNAs,
one snoRNA, and eight pseudogenes (Table 5). Within the
group where gene expression was lower in old compared
with young tendon, 112 were known protein-coding genes.
The remaining 22 genes contained 16 lncRNAs, one
snoRNA, four pseudogenes, and a single microRNA
(miRNA) (Table 6). Thus, 325 genes were input into IPA
for downstream analysis, and 273 of these were mapped.
The analysis identified a number of transcript iso-
forms expressed in tendon, some of which were differ-
entially expressed between young and old groups of tendon
(Figure 2). In total, 183,660 isoforms were detected in young
and 191,673 isoforms were detected in old tendon. Among
these, 21,193 isoforms were detected only in young and
29,206 isoforms only in old. Sixty-three known isoforms
were upregulated in old tendon, with 80 downregulated
with an FDR-adjusted P value of less than 0.05 and ±1.4
log2 fold regulation. The top 10 up- and down-regulated
isoforms are presented in Table 7. The entire list of signifi-
cantly DEG isoforms is presented in Additional file 3.
Age-related changes in transcription factors
There was an increase in the expression of 12 transcrip-
tion factors in tendon derived from older donors
Table 1 Gene primer sequences used in RNA-Seq validation
Name Gene type Ensemble gene ID/transcript ID Primer sequence
RPS16 Protein-coding ENSG00000105193 F: GAAATCCTACCGATAAGCCCA
R: TTTCTTGAAACTTTAAAATCCCTCAA
MMP3 Protein-coding ENSG00000149968 F: ATTCCATGGAGCCAGGCTTTC
R: CATTTGGGTCAAACTCCAACTGTG
COL1A1a Protein-coding ENSG00000108821 F: GGAGGAGAGTCAGGAAGG
R: GCAACACAGTTACACAAGG
ACANb Protein-coding ENSG00000108821 F: TCGAGGACAGCGAGGCC
R: TCGAGGGTGTAGCGTGTAGAGA
POU3F4 Protein-coding ENSG00000196767 F: GTTCGCTCGCTCTCTCGTA
R: GAAGGGAAGGGAAGGGGAAA
MYF5 Protein-coding ENSG00000111049 F: TGAACTAATTTTCTGGTCTATATGAC
R: TGTACATGTTGTCTTGGTTTGGG
IGF1 Protein-coding ENSG00000017427 F: CACTATGGACAGATGTAAAAGAAACTA
R: ACACACTGGGGACAAGAAATAAA
MMP16 Protein-coding ENSG00000156103 F: ACCCGTGTAACCCTTTGAGA
R: AACCTGAACTTCTTGAACTTGTG
TGFB3 Protein-coding ENSG00000119699 F: GTAAAGAAAGTGTGGGTTTGGTTA
R: AACATCTCAACTTACCATCCCTTT
EGF Protein-coding ENSG00000138798 F: ACAGGAGGCTTCGGAGTT
R: AATCAGGCAATTTACTTACAATCTT
COL3A1-001 Protein-coding ENST00000304636 F: CAGGTCCCAGCGGTTCT
R: CCTTTTGGTCCAGACACTCC
COL3A1-201 Protein-coding ENST00000317840 F: GGTAGCCCTGGTGAGAGAG
R: TGCCAGGAGGTCCAAAGAG
FGF10-001 Protein-coding ENST00000264664 F: TGCCGTCAAAGCCATTAACA
R: CATTTTCCTCTATCCTCTCCTTCA
CRTAC1-001 Protein-coding ENST00000370597 F:ATCTTCTTCAACAACATTGCCTAC
R: GGGTCTCCGTGCTCTCTAC
IGF1-001 Protein-coding ENST00000337514 F: CAGCAGTCTTCCAACCCAAT
R: AAGAGATGCGAGGAGGACAT
XIST Lnc ENSG00000229807 F: TCCCAGAGAATGCCTAATACTTT
R: GTAGAAGAGATACGGAGTAGGAAT
LINC00957 Lnc ENSG00000235314 F: GAGAGTAAGCAGACCTGGGT
R: ACCTTGTCCGAGTTCCATCT
RP11.308 N19.1 Lnc ENSG00000234323 F: GCCTCTTTCATCACTGCCGA
R: TAGCAGCAGTTGGGGTGTTT
a[40] and b[41] denote primer pairs published previously. F, forward; Lnc, long non-coding; R, reverse.
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gene enhancer protein 1 (ISL1), lim homeobox 9 (LHX9),
myocardin (MYOCD), POU domain, class 3, transcription
factor 4 (POU3F4), POU3F3, paired box transcription fac-
tor 3 (PAX3), PAX6, PAX9, thyroid transcription factor 1
(NKX2-1), NKX6-1, and dachshund family transcription
factor 2 (DACH2). In comparison, there was an increase
in only three in younger donors: basic helix-loop-helixfamily, member e40 (BHLHE40), early growth response 2
(EGR2), and zinc finger of the cerebellum 3 (ZIC3).
Differentially expressed genes and network analysis
DEGs (325) and differentially expressed transcript iso-
forms (143) associated with ageing were analysed to-
gether in IPA with the following criteria: P value of less
than 0.05 and 1.4 log2 fold change. Network-eligible
Table 2 Summary of sequence alignment to the human genome
Sample Reads to
aligna
Reads aligned to
genome
Percentageb Reads properly
paired
Percentagec Reads with mate
unmapped
Percentaged Percentage of
‘expressed’ genese
Young 1 61,516,106 55,995,223 91.03 51,821,068 92.55 4,174,155 7.45 46.65
Young 2 74,068,430 67,565,304 91.22 62,477,226 92.47 5,088,078 7.53 45.98
Young 3 65,954,168 60,771,423 92.14 56,659,046 93.23 4,112,377 6.77 47.19
Young 4 59,947,540 53,381,917 89.05 48,909,710 91.62 4,472,207 8.38 40.58
Young 5 89,707,092 80,798,459 90.07 74,516,846 92.23 6,281,613 7.77 45.01
Old 1 62,712,522 57,345,261 91.44 53,413,212 93.14 3,932,049 6.86 46.42
Old 2 46,590,704 41,788,780 89.69 38,331,156 91.73 3,457,624 8.27 40.46
Old 3 61,364,402 55,643,829 90.68 51,415,610 92.40 4,228,219 7.60 46.36
Old 4 55,361,082 49,725,122 89.82 45,615,238 91.73 4,109,884 8.27 42.44
Maximum 89,707,092 80,798,459 92.14 74,516,846 93.23 6,281,613 8.38 47.4
Mean 65,591,734 59,482,205 90.65 54,953,876 92.36 4,528,330 7.64 44.92
Minimum 46,590,704 41,788,780 89.05 38,331,156 91.62 3,457,624 6.77 40.46
The table shows the number and percentage of reads mapped to the human reference sequences. aSum of R1 and R2 reads used in the alignment. bPercentage
of reads used in the alignment that align to the reference genome. cPercentage of reads used in the alignment that align to the reference genome in the correct
relative orientation to their mate. dPercentage of reads used in the alignment that align to the reference genome but whose mate does not align. ePercentage of
63,152 annotated human genes with at least one read aligned.
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on information from the ingenuity pathway knowledge
database and networks generated based on connectivity.
(See Additional file 4 for all identified networks and
their respective molecules.)
The top four scoring networks for genes differentially
expressed with tendon age were from cellular function
and maintenance, cellular growth and proliferation, cel-
lular cycling, and cellular development (Figure 3). Sig-
nificant IPA canonical pathways are demonstrated in
Table 8, and the associated molecules of the top canon-
ical pathways identified are in Additional file 5. These
include hepatic fibrosis, oestrogen biosynthesis, and
transcriptional regulatory networks in embryonic stem
cells. Interestingly, skeletal and muscular disorders were
identified as one of the top diseases associated with the
gene set (Additional file 6).
Functional annotation of up- and down-regulated
isoforms
There was a reduction in the DEG isoforms of 32 genes
(representing 15% of the data set) relating to the ECM,
degradative proteases, cytokines, and growth factors in
tendon derived from older donors compared with young
donors. In comparison, there was an increase in only
two ECM genes (representing 1.3% of the data set) in
older donors (data not shown). DAVID identified signifi-
cant gene ontology (GO) terms in the upregulated and
downregulated set of transcript isoforms (Table 9) with
only two terms ‘secreted’ and ‘signal’ overlapping be-
tween the two groups. Interestingly, other terms are
strikingly different between the upregulated and down-
regulated isoform data sets. Several of the top GO termsidentified in downregulated isoforms in old tendon re-
late to collagen and post-translational modification of
collagen (for example, hydroxylation, hydroxylysine, hy-
droxyproline, and triple helix).
Confirmation of DEG by using qRT-PCR measurements of
selected genes
To validate the RNA-Seq technology, selected gene ex-
pression differences noted in the RNA-Seq analysis were
re-measured by using reverse transcription and qRT-PCR.
This was performed on the original RNA from all donors
used to perform the RNA-Seq experiment (Table 10) and
an independent cohort (Additional file 7A). All genes were
found to have comparable results with RNA-Seq data; for
instance, genes identified as having an increase in expres-
sion in older samples in the RNA-Seq experiment also
gave increased expression relative to RPS16 following
qRT-PCR. Statistical significance was tested by using
Student’s t test. Two genes whose expressions were not
significantly altered in RNA-Seq results—aggrecan
(ACAN) and MMP3—were also unaltered when assessed
with qRT-PCR. Gene expression analysis using qRT-PCR
of an independent cohort found similar results. Validation
of differential isoform expression by using qRT-PCR
was in general concordance with RNA-Seq (Additional
file 7B). In all cases, the level of expression varied be-
tween the two platforms.
Discussion
Ageing is recognised as a significant risk factor for tendon
injury; however, knowledge of changes to the transcrip-
tome of tendon cells has previously been limited to that
gained from quantitative PCR [5,48,49] and microarray
Table 3 Top 25 genes
Gene name Name Log fold change FDR-adjusted Mean FPKM
RN7SK 7SK small nuclear 0.1 1.0 22,323.9
RN7SL2 RNA, 7SL, cytoplasmic 2 −0.5 0.7 12,212.2
RN7SL4P RNA, 7SL, cytoplasmic, pseudogene 1 −0.6 0.6 5,813.8
RN7SL1 RNA, 7SL, cytoplasmic 2 −1.1 0.5 3,846.0
ANGPTL7 Angiopoietin-like 7 0.4 0.8 3,529.0
RNA28S5 Ribosomal RNA 18S 6 −0.3 0.9 3,374.0
RN7SKP255 7SK small nuclear pseudogene 255 0.1 1.0 2,898.5
RN7SKP203 7SK small nuclear pseudogene 203 −0.1 1.0 2,836.7
S100A6 S100 calcium binding protein A6 0.1 0.9 1,950.3
MALAT1 Metastasis associated lung adenocarcinoma transcript 1 0.0 1.0 1,801.5
DCN Decorin 0.0 1.0 1,791.5
RN7SL5P RNA, 7SL, cytoplasmic, pseudogene 2 −1.3 0.4 1,774.0
THBS4 Thrombospondin 4 −0.8 0.6 1,368.2
MT-CO1 Mitochondrial cytochrome c oxidase III −0.6 0.6 1,230.9
TMSB10 Thymosin beta 10 −0.3 0.7 1,220.1
ASPN Asporin −1.6 0.5 1,145.3
MMP3 Matrix metallopeptidase 3 2.2 0.2 1,126.7
RNA18S5 Ribosomal RNA 28S 5 −0.2 0.9 1,125.5
CLU Clusterin 0.3 0.9 1,106.6
MT-ND3 Mitochondrial NADH dehydrogenase 3 −0.5 0.6 1,036.1
LUM Lumican 0.0 1.0 978.9
VIM Vimentin 0.2 0.9 977.1
CILP Cartilage intermediate layer protein 0.3 0.9 920.8
EEF1A1 Eukaryotic translation elongation factor 1 alpha-like 7 0.0 1.0 891.4
IGFBP6 Insulin-like growth factor-binding protein 6 0.7 0.6 859.0
The table demonstrates the 25 most highly expressed genes in young and old tendon in terms of transcript expression as determined by using fragments per
kilobase of exon per million fragments mapped (FPKM). FDR, false discovery rate.
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[17,52]. In this study, we report for the first time the use
of the RNA-Seq technique to undertake deep transcrip-
tome profiling of young and old macroscopically normal
human Achilles tendon. Importantly, validation studies
using qRT-PCR demonstrated high correlation between
methodologies and demonstrated reproducibility using a
different donor set. One of the many advantages of RNA-
Seq over microarrays is that it enables de novo analysis of
transcripts, including novel transcripts. In this study, we
were able to identify and quantify protein-coding tran-
scripts, alternatively spliced isoforms, lncRNAs, pseu-
dogenes, and small regulatory RNAs, including small
nucleolar RNAs (snoRNA) and an miRNA. The age of the
donor accounted for most of the variability in the data, al-
though PCA identified more variability between young do-
nors. We did not have access to detailed medical history
and lifestyle factors for the patients in this study, so we are
unable to determine whether other factors explain the
variability more precisely.Tendon is characterised by a large amount of ECM in-
terspersed around a relatively sparse population of cells.
The main component of the matrix is the fibril-forming
type I collagen, which composes about 70% of the dry
weight of the matrix [53]. Minor collagen types include
other fibril-forming collagens, type III and V; fibril-
associated collagens, type XII and XIV; and type VI colla-
gen. As expected, these were the main collagen genes we
identified in the transcriptome of the Achilles tendon tis-
sue, albeit at relatively low levels. The non-collagenous
component of tendon is rich in small leucine-rich proteo-
glycans (SLRPs), including decorin, biglycan, fibromodu-
lin, and lumican, and the glycoproteins COMP, lubricin,
tenomodulin, and tenascin C [54]. Interestingly, the results
of this study show that decorin was by far the most highly
expressed ECM gene across the samples in comparison
with relatively low levels of collagen transcripts. Lumican
was the next most highly expressed ECM protein followed
by fibromodulin and COMP. These results are in line with
our recent proteomics study in which decorin was the
Figure 1 Principal component analysis (PCA) and volcano plot of differentially abundant transcripts. (A) PCA plot of log2 gene expression
data showed the greatest variability in RNA-Seq data was due to the age of the donor. The second and third components are also shown as
changes in the first and second components are due to differing sample sizes between young and old groups. (B) Volcano plot represents log2
FC × log2 CPM plot (counts per million mapped reads) CPM plot. Low expression genes (log2 CPM of less than −5) are coloured orange. Significant
differentially expressed genes (DEGs) are coloured in red. A set of DEGs between young and old tendon was identified. With the common dispersion
in edgeR [30], 325 DEGs were identified with a P value of less than 0.05 (red).
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Table 4 Top 10 genes with the highest and lowest log2 fold change when comparing young and old tendon
Condition increased
differential expression
Gene
symbol
Gene name Location Function Log2 fold
change
Old CYP24A1 Cytochrome P450, family 24, subfamily A,1 Cytoplasm Enzyme 9.3
FOLH1B Folate hydrolase 1B Cytoplasm Enzyme 8.8
POU3F4 POU class 3 homeobox 4 Nucleus Transcription regulator 8.3
FOLH1 Folate hydrolase 1 Plasma
membrane
Peptidase 7.7
BRS3 Bombesin-like receptor 3 Plasma
membrane
G-protein coupled
receptor
7.6
XIST X (inactive)-specific transcript (non-protein coding) Variable Long non-coding RNA 6.9
EGF Epidermal growth factor Extracellular
space
Growth factor 6.5
BRINP3 Bone morphogenetic protein/retinoic acid inducible
neural-specific 3
Secreted/
mitochondria
Osteoblast
differentiation factor
6.5
NXPH2 Neurexophilin 2 Extracellular
space
Signalling molecules 6.5
MYF5 Myogenic factor 5 Nucleus Transcription regulator 6.4
Young CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 Cytoplasm Enzyme −7.6
CLEC3A C-type lectin domain family 3, member A Secreted Cell adhesion −6.1
DIRAS1 DIRAS family, GTP-binding RAS-like 1 Plasma
membrane
Enzyme −5.9
SYT13 Synaptotagmin XIII Plasma
membrane
Transporter −5.6
GPR143 G protein-coupled receptor 143 Plasma
membrane
G-protein coupled
receptor
−5.6
SLC7A14 Solute carrier family 7 member 14 Plasma
membrane
Transporter −5.4
HIST 1H3A HISTONE 1H3A Nucleus Nucleosome −5.4
PYCR1 Pyrroline-5-carboxylate reductase 1 Cytoplasm Enzyme −5.3
UTS2R Urotensin 2 receptor Plasma
membrane
G-protein coupled
receptor
−5.2
HBG1 Hemoglobin, gamma A Cytoplasm Fe carrier −4.9
Log2 fold change and q value (adjusted P value) were determined in edgeR. A logarithm to the base 2 of 9 is approximately a linear fold change of 3.2. Shown are
the 10 genes with highest and lowest expression in old compared with young tendon samples.
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uble extract of equine flexor tendon [55]. Degradation of
the ECM is accomplished by a family of MMPs along with
other proteases, and we identified expression of collage-
nases, stromelysins, gelatinases, and aggrecanases, al-
though in general the levels of expression were low. An
exception to this was MMP3, a stromelysin responsible
for proteoglycan degradation, which was one of the most
abundant transcripts, again supporting the finding of a
higher turnover of non-collagenous proteins.
Ageing results in changes to the tendon ECM compos-
ition, although these are poorly defined at present and
the impact on tendon mechanical properties is not clear
as some studies report increased stiffness with ageing
[56,57] whereas others report a decrease [58,59]. A re-
cent study using equine flexor tendon found that, al-
though the mechanical properties of the gross structure
and the component fascicles did not change with age,the inter-fascicular matrix became stiffer. Given this
finding, we expected to find differential expression of
ECM transcripts, particularly those enriched in the
inter-fascicular matrix. The differential gene expression
analysis showed no regulation of proteins likely to be
enriched in the inter-fascicular matrix or inter-fibrillar
proteins [54]. The alpha 1 chain of type I collagen and
alpha 1 chain of type III collagen were identified as hav-
ing reduced expression in the old age group, although
this lost statistical significance when measured by qRT-
PCR on a larger sample set. For the most part, these
data do not support our original hypothesis that tendon
ageing results in reduced expression of genes relating to
ECM, degradative proteases, cytokines, and growth fac-
tors, unlike changes evident in ageing cartilage [24].
Tendon disease, which has a clear association with
ageing, has been the focus of several gene expression
studies. Generally, findings in these studies are in
Table 5 Non-coding RNAs significantly overexpressed in old tendon
Gene accession Category Type of
transcript
Log2 fold
change
Description/Aliases Function
RNVU1-6 SnoRNA Small nuclear 4.9 Variant U1 small nuclear 6 Splicesomal
RP11-578O24.2 Pseudogene Pseudogene 6.2 Unknown
AP003041.1 Pseudogene Pseudogene 5.3 Unknown
MKRN7P Pseudogene Pseudogene 4.8 Makorin ring finger protein 7 Unknown
RPS4XP22 Pseudogene Pseudogene 4.1 Ribosomal protein S4X pseudogene 22 Unknown
RP11-346 M5.1 Pseudogene Pseudogene 2.8 Unknown
RN7SKP234 Pseudogene Pseudogene 2.4 RNA,7SK small nuclear pseudogene 243 Unknown
CTD-2114 J12.1 Pseudogene Pseudogene 2.1 Unknown
AL021068.1 Pseudogene Pseudogene 1.9 Unknown
CTD-2083E4.4 LncRNA Novel processed 2.3 Unknown
RP3-326 L13.3 LncRNA Novel lncRNA 7.1 Unknown
RP11-377D9.3 LncRNA Novel lncRNA 6.3 Inc-KIAA1467-2 Unknown
RP11-71E19.2 LncRNA Novel lncRNA 5.4 Inc-KLF15-2 Unknown
AC073636.1 LncRNA Novel lncRNA 5.1 Inc-NFE2L2-3 Unknown
RP11-279 F6.1 LncRNA Novel lncRNA 4.7 Inc-RPLP1-1 Unknown
AC004510.3 LncRNA Novel lncRNA 4.1 Unknown
RP11-500B12.1 LncRNA Novel lncRNA 4.1 Inc-TLR4-1 Unknown
AC007405.6 LncRNA Novel lncRNA 3.8 Inc-AC007405.7.1-1 Unknown
RP11-399D6.2 LncRNA Novel lncRNA 3.5 Inc-DMRTA1-2 Unknown
RP11-966I7.1 LncRNA Novel lncRNA 3.5 Inc-PRKD1-8 Unknown
RP11-815 M8.1 LncRNA Novel lncRNA 3.1 Inc-DUSP10-3 Unknown
AC003090.1 LncRNA Novel lncRNA 2.4 Inc-NPVF5 Unknown
RP11-79H23.3 LncRNA Novel lncRNA 2.2 Inc-FAM164A-1 Unknown
RP11-4 F5.2 LncRNA Novel lncRNA 2.0 Inc-MCTP2-1 Unknown
RP5-1024G6.8 LncRNA Novel lncRNA 1.9 Unknown
NKX2-1-AS1 LncRNA Novel antisense 7.4 NKX2-1 antisense RNA 1 Unknown
RP3-326 L13.2 LncRNA Novel antisense 6.5 Unknown
RP11-464O2.2 LncRNA Novel antisense 5.4 Inc-LHPP-1 Unknown
AC091633.3 LncRNA Novel antisense 5.4 Inc-MUC20-2 Unknown
RP11-711G10.1 LncRNA Novel antisense 5.3 Unknown
SATB2-AS1 LncRNA Novel antisense 4.2 SATB2 antisense RNA 1 Unknown
FEZF1-AS1 LncRNA Novel antisense 4.1 FEZF1 antisense RNA 1 Unknown
SLC26A4-AS1 LncRNA Novel antisense 3.7 SLC26A4 antisense Unknown
RP11-160A10.2 LncRNA Novel antisense 3.5 Inc-CLVS2 Unknown
RP4-803 J11.2 LncRNA Novel antisense 3.4 Inc-RAB4A-1 Unknown
RP11-402 J6.1 LncRNA Novel antisense 2.5 Inc-ALPK1-1 Unknown
RP11-710C12.1 LncRNA Novel antisense 2.0 Unknown
XIST LncRNA Known lncRNA 7.0 X inactive specific transcript X chromosomal inactivation
LINC00261 LncRNA Known lncRNA 5.9 LINC RNA 261 Inc FOXA2-2 Cancer
TSIX LncRNA Known lncRNA 3.9 TSIX transcript, XIST antisense RNA Antisense during X chromosomal inactivation
LINC00461 LncRNA Known lncRNA 2.5 INC MEF2C-2 Unknown
DLX6-AS1 LncRNA Known antisense 2.7 Embryonic ventral forebrain-1 Gene expression; hippocampus
Genes here have at least a ±1.4 log2 fold change and false discovery rate-adjusted P value of less than 0.05 as determined by edgeR. LncRNA, long-coding RNA;
SnoRNA, small non-coding RNA.
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Table 6 Non-coding RNAs with significantly reduced expression in old tendon
Gene
accession
Category Type of transcript Log2 fold
change
Description/Aliases Function
LINC00957 LncRNA Novel lncRNA −1.73 Long intergenic non-coding RNA 957 Unknown
ZNF667-AS1 LncRNA Novel lncRNA −1.82 ZNF667 antisense RNA 1 (head to
head)
Unknown
RP11-308 N19.1 LncRNA Novel lncRNA −2.43 Unknown
AF131215.9 LncRNA Novel sense
intronic
−2.78 Unknown
CTB-113P19.1 LncRNA Novel antisense −2.93 Inc-G3BP1-2 Unknown
AF131215.2 LncRNA Novel sense
intronic
−3.24 Unknown
MAFG-AS1 LncRNA Known antisense −3.45 MAFG antisense RNA 1 (head to head) Unknown
AC020571.3 LncRNA Novel antisense −3.50 Inc-CCDC150-1 Unknown
AC012613.2 LncRNA Novel antisense −3.86 Inc-IL17B-3 Unknown
RP11-923I11.1 LncRNA Novel antisense −3.91 Inc-SCN8A-1 Unknown
RP11-270 M14.5 LncRNA Novel lncRNA −4.01 Inc-TTLL5-1 Unknown
CTD-2540B15.9 LncRNA Novel lncRNA −4.50 Novel lincRNA Unknown
CTD-3049 M7.1 LncRNA Novel lncRNA −4.53 Inc-RGMA7 Unknown
RP5-1198O20.4 LncRNA Novel lncRNA −5.25 Inc-KLF17-1 Unknown
RP11-300E4.2 LncRNA Novel antisense −6.24 Inc-JPH1_5 Unknown
RP11-445 L6.3 LncRNA Novel lncRNA −6.31 Inc-TNC-2 Unknown
MIR1245A MiRNA Known miRNA −2.15 Unknown
MXRA5P1 Pseudogene Pseudogene −3.52 MXRA5P1 Unknown
RNY3P2 Pseudogene Pseudogene −5.30 RNA Ro-associated Y3 pseudogene 2 Unknown
RP11-494 K3.2 Pseudogene Pseudogene −6.36 Unknown
CTC-260E6.10 Pseudogene Pseudogene −7.23 Unknown
Y_RNA SnoRNA Novel misc RNA −5.53 DNA replication and cell
proliferation
Terms are derived from Ensemble [46] and Vega [47]. ‘Antisense’ overlaps the genomic span of a protein-coding locus on the opposite strand. ‘Known’ indicates
identical to known cDNA or proteins from the same species and has an entry in a model database. ‘Novel’ indicates identical or homologous to cDNAs from the
same species or proteins from all species. ‘Processed transcript’ does not contain open reading frame and cannot be placed in any other category. ‘Pseudogene’
indicates homology to protein but from a disrupted coding sequence and an active homologous gene can be found at another locus. ‘Sense intronic’ has a long
non-coding transcript in introns of a coding gene that does not overlap any exons. LncRNA, long non-coding RNA (which can be further classified as LINCRNA,
which is a long interergenic non-coding RNA locus of more than 200 base pairs); miRNA, microRNA; SnoRNA, small non-coding RNA.
Peffers et al. Arthritis Research & Therapy  (2015) 17:33 Page 11 of 18keeping with the hypothesis of increased matrix turn-
over, with an imbalance favoring catabolism. For ex-
ample, various studies have demonstrated increased
expression of collagen 1 alpha 1 (COL1A1) [5,48,49]
and proteins more typical of cartilage COL2A1,
aggrecan, and SOX9 [5,52]. Tendinopathic samples
show an upregulation of various MMPs, including
MMP23 [5,51], a disintegrin and metalloproteinase 12
(ADAM12) [5,50,51], and downregulation of MMP3.
The results of our study are in stark contrast to this
with very low expression levels for COL2A1, aggrecan,
SOX9, most MMPs (except MMP3), and a significant
downregulation of ADAM12 in the old group. There-
fore, the results suggest that degeneration is not an in-
evitable consequence of ageing and that ageing and
disease-associated degeneration are distinct processes.In this study, we identified DEG gene sets with ageing
related to a dysregulation of cellular function and main-
tenance, cellular growth and proliferation, cellular cyc-
ling, and cellular development. Therefore, these changes
suggest that the cellular component of tendon may lose
the ability to respond appropriately to mechanical and
chemical signals. Other studies have linked cellular sen-
escence, a state of irreversible growth arrest, in a small
subset of cells (progenitor cells) in tendon with tendon
ageing [60]. A senescence phenotype has been described,
although no marker of senescence identified thus far is
entirely specific to the senescent state [9]. Most senes-
cent cells express p16(INK)4a, which is not commonly
expressed by quiescent or terminally differentiated cells
[9]. In this study, p16(INK)4a was expressed at higher
levels in the old group, although transcript levels overall
Table 7 List of top 10 up-/down-regulated isoforms in ageing tendon
Comparison Gene Locus Log2 (fold change) q value
Higher in old PM20D2 6:89855768-89875284 0.54 0.04
ILF3-AS1 19:10762537-10764520 0.62 0.01
PERP 6:138411922-138428648 0.65 0.03
ODC1 2:10580093-10588630 0.67 0.03
PRKAA2 1:57110994-57181008 0.68 0.03
PNRC1 6:89790469-89794879 0.69 0.02
SYT11 1:155829299-155854990 0.70 0.02
F13A1 6:6144317-6321246 0.71 0.01
CITED2 6:139693392-139695757 0.72 0.01
LDB1 10:103867316-103880210 0.73 0.01
Lower in old HLA-DRB5 6:32485119-32498064 −4.72 0.01
MYH1 17:10286448-10527201 −4.52 0.01
CRABP2 1:156669397-156675608 −4.44 0.03
CPXM1 20:2774714-2781283 −4.29 0.01
COL3A1 2:189839045-189877472 −4.16 0.01
COL3A1 2:189839045-189877472 −3.87 0.01
ADAM12 10:127700949-128077024 −3.84 0.01
CAPN6 X:110488330-110513751 −3.72 0.03
COL1A1 17:48260649-48278993 −3.46 0.01
FAP 2:163018279-163101661 −3.37 0.01
The differentially expressed genes (DEGs) in young versus old tendon were determined by Cuffdiff. The fold change is the ratio of fragments per kilobase of exon
per million fragments mapped (FPKM) of those genes in young to FPKM of those genes in old tendon. The significant DEGs (q values of less than 0.05) calculated
with a Benjamini-Hochberg correction were ranked on their log2 fold change, and 10 genes with the highest or lowest fold changes are shown in the table.
Figure 2 Volcano plot showing significant differentially expressed (DE) isoforms between young and old tendon. Following assembly
with Cufflinks of alternative splicing transcripts [36], significant DE transcripts were identified with q values (P value adjusted to false discovery
rate) of less than 0.05. Red spots represent significant DE isoforms, and black spots are for non-DE isoforms.
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Figure 3 Top-scoring networks derived from the 325 genes differentially expressed in ageing. (A) Ingenuity pathway analysis (IPA)
identified from cellular function and maintenance as the principal associated network functions with scores of 43. (B) The second top-scoring
network was a cellular growth and proliferation, with scores of 32. (C) IPA identified cell cycle and skeletal and muscular system development function
with a score of 32. (D) The fourth top-scoring network was cellular development, with a score of 28. Figures are graphical representations between
molecules identified in our data in their respective networks. Green nodes indicate upregulated gene expression in older tendon; red nodes indicate
downregulated gene expression in older tendon. Intensity of colour is related to higher fold change. The key to the main features in the networks
is shown.
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of cells is responsible for the difference. Senescent cells
have been shown to contribute to an inflammatory profile,
and the term ‘inflamm-aging’ has been coined [13]. Stud-
ies have shown upregulation of inflammatory mediators
such as cytochrome oxidase 2 (COX2), interleukin 6 (IL-
6), and prostaglandin E2 (PGE2) and downregulation ofthe lipoxin A4 (LXA4) receptor FPR2 (formyl peptide re-
ceptor 2)/ALX in human or equine tendinopathic tissue
[14,49]. Inflammatory pathways, however, were not recog-
nised in our GO mapping of DEGs between young and
old groups in this study.
An interesting finding in this study was the differential
expression of isoforms and those with reduced expression
Table 8 A number of ingenuity pathway analysis
canonical pathways were significantly affected in ageing
tendon
Name of canonical pathway P value Ratio
Hepatic fibrosis/Hepatic stellate cell
activation
5.69 × 10−4 8/142 (0.056)
Oestrogen biosynthesis 1.61 × 10−3 4/38 (0.105)
Transcriptional regulatory network in
embryonic stem cells
1.95 × 10−3 4/40 (0.1)
Glioblastoma signalling 3.66 × 10−3 7/159 (0.044)
Bupropion degradation 4.89 × 10−3 3/26 (0.115)
The significance of the association between the data set and the canonical
pathway was measured by using a ratio of the number of molecules from the
data set that mapped to the pathway divided by the total number of
molecules that map to the canonical pathway. Fisher’s exact test was used to
calculate P values.
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ases, cytokines, and growth factors. AS is a significant
regulatory mechanism in gene expression as it enables ver-
satility at the post-transcriptional level accounting for
proteome complexity and may affect up to 92% of humanTable 9 Significant gene ontology terms annotated
according to DAVID’s SP-PIR-Keywords
Term Count Percentage P value
GO terms identified in downregulated isoforms in old tendon
Signal 88 45.1 6.30 × 10−18
Secreted 58 29.7 7.04 × 10−15
Extracellular matrix 24 12.3 3.25 × 10−14
Glycoprotein 85 43.6 2.72 × 10−9
Collagen 12 6.2 1.62 × 10−7
Trimer 7 3.6 8.71 × 10−6
Hydroxylation 9 4.6 2.22 × 10−5
Triple helix 7 3.6 2.00 × 10−5
Hydroxylysine 7 3.6 2.00 × 10−5
Disulfide bond 57 29.2 1.85 × 10−5
Cell adhesion 18 9.2 3.57 × 10−5
Hydroxyproline 7 3.6 4.38 × 10−5
Ehlers-Danlos syndrome 5 2.6 7.34 × 10−5
Angiogenesis 6 3.1 0.011506
Metalloprotease 8 4.1 0.016954
Pyroglutamic acid 5 2.6 0.021871
GO terms identified in upregulated isoforms in old tendon
Secreted 30 24.2 1.48 × 10−4
Plasma 7 5.6 0.003767
Signal 39 31.5 0.006761
Acute phase 4 3.2 0.052997
Gene ontology (GO) terms were revealed in upregulated and downregulated
differentially expressed gene isoforms of tendon ageing. P value represents
Benjamini-Hochberg corrected P value. DAVID, Database for Annotation,
Visualization and Integrated Discovery.genes [61]. Differences between isoforms of the same pro-
tein extend from a complete loss of function, acquiring a
new function to subtle modulations, the latter observed in
the majority of cases [62]. Few AS events have been re-
ported in tendon to date. Those that have include versican,
in which AS may contribute to changes in ECM structure
and function in tendinopathies [48]; lubricin, which is
location-dependent [63]; and insulin-like growth factor 1,
which is mechanical stress-dependent [64]. The isoforms
showing the greatest difference between young and old
tendon groups in our study (for example, COL1A1,
COL3A1, and ADAM12) are recognised as some of the
most important proteins for tendon function and the rele-
vance of these isoforms requires further investigation.
The results of our study have yielded new information
relating to tendon cell phenotype and to the ageing
process, identifying transcripts that are not generally
recognised as being important in tendon. For example,
the gene most highly expressed, disregarding ribosomal
proteins, was angiopoetin-like 7 (ANGPTL7). This pro-
tein has previously been identified as highly expressed in
microarray analysis of human tendinopathic tissue from
various tendons [50]. Angiopoetins are involved in
angiogenesis [65], inflammation, and glucose [66] and
lipid [67] metabolism. In the cornea, ANGPTL7 may
function as negative regulator of angiogenesis, contribut-
ing to the avascular properties of the tissue [68], whereas
in the human ocular trabecular meshwork cells, it has a
role in the organization of the ECM [69]. Thus, we sug-
gest that ANGPTL7 may have a role in maintaining the
relatively avascular nature of tendon tissue and in the or-
ganisation of the ECM. This represents an area for fur-
ther investigation.
One of the limitations of this study is that the samples
were taken from patients with malignant disease. We con-
sider that it is very unlikely that this has influenced the re-
sults as samples are taken only when the tumour is at a
site distant to the tendon and the tendon is macroscopic-
ally normal; however, we cannot rule out the possibility
that some of the genes showing high expression, such as
metastasis associated lung adenocarcinoma transcript 1
(MALAT1), ANGPITL7, and S100A6, are related to the
disease state.
Another point of interest was the expression of genes
associated with muscle cells. For example, we observed a
reduced DEG of myosin heavy chain 1 and an increase
DEG of myogenic factor 5 (MYF5) and MYOCD. Our pre-
vious studies in ageing cartilage also identified DEG of
muscle-related genes: myosin heavy chain 2, myosin 3A,
and myosin 1B, which were all reduced in cartilage ageing
[24]. Samples of Achilles tendon were taken at a region far
removed from muscle insertion, and the identification of
muscle genes in cartilage and tendon is unlikely to be due
to inadvertent inclusion of muscle tissue.
Table 10 Real-time polymerase chain reaction analysis of 14 selected genes reveals good correlation with RNA-Seq
results
Gene name RNA-Seq results RT-PCR results
Age P value
Differential expression Significant log2 fold change q value Young Old
EGF Higher in old 6.50 2.06 × 10−8 0.003 ± 0.002 0.01 ± 0.007 0.04
POU3F4 8.20 7.79 × 10−16 0.021 ± 0.015 0.245 ± 0.147 0.02
MYF5 6.30 0.003 0.061 ± 0.057 0.25 ± 0.07 0.01
TGFB3 Lower in old −1.60 0.035 10.717 ± 6.022 0.897 ± 0.34 0.05
MMP16 −2.30 0.022 0.107 ± 0.087 0.014 ± 0.02 0.07
COL3A1 −3.70 0.008 13.696 ± 17.535 1.05 ± 0.594 0.27
MYH1 −4.60 0.003 0.288 ± 0.155 0.14 ± 0.101 0.23
IGF1 −2.10 0.004 2.094 ± 1.234 0.483 ± 0.278 0.04
COL1A1 −3.30 0.009 47.968 ± 32.676 8.515 ± 9.154 0.42
MMP3 No change Not significant 1.000 51.181 ± 362.11 99.323 ± 66.10 0.15
ACAN 1.000 1.439 ± 1.43 0.848 ± 0.99 0.66
XIST Higher in old 6.90 0.000 0.827 ± 0.712 7.41 ± 3.465 0.03
LINC00957 Lower in old −1.70 0.036 1.044 ± 0.584 0.363 ± 0.174 0.08
RP11.308 N19.1 −2.430 0.040 0.02 ± 0.065 0.005 ± 0.001 0.03
Values for real-time polymerase chain reaction (RT-PCR) are the mean ± standard deviation of relative expression levels normalised to expression of RSP16 (to two
decimal places). Statistical significance was tested by using Student’s t test. RT-PCR results are expressed as 2^-DCT. ACAN, aggrecan; COL1A1, collagen type 1
alpha 1; COL3A1, collahen type 3 alpha 1; EGF, epidermal growth factor; IGF1, insulin growth factor 1; LINC00957 long intergenic non-protein coding RNA 957;
MMP3, matrix metalloproteinase; MMP16, matrix metalloproteinase 16; MYF5, myogenic factor 5; MYH1, myosin heavy chain 1; POU3F4, POU class 3 homeobox 4;
RP11.308 N19.1, Inc-ZNF462-2; TGFB3, transforming growth factor β.
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of a large set of transcription factors in old compared
with young tendon. In Caenorhabditis elegans [70] and a
number of tissues, including heart [71] and brain [72],
transcription factors have been implicated in ageing.
Interestingly, deacetylates Nk2 homeobox 1 (NKX2-1), a
transcription factor showing upregulation in old tendon
in our study, is involved in neuronal activation in dor-
somedial and lateral hypothalamic nuclei, a function
thought to contribute to a more ‘youthful’ physiology
during ageing [73]. Conversely, an isoform of scleraxis
(SCX), a critical transcription factor in tendon develop-
ment [74], was reduced in old tendon. In addition, the
reduced expression in old tendon of EGR2 and AS
EGR1, both of which are required for tendon differenti-
ation [75], may affect tendon repair [76].
We identified eight pseudogenes showing upregulation
in the old group of tendons. Pseudogenes have similar se-
quences to their counterpart coding genes, but owing to
mutation/deletion or insertion of nucleotides they cannot
be transcribed. It is hypothesised that pseudogenes act as
post-transcriptional regulators of the corresponding par-
ental gene [74]. In other studies, pseudogenes have been
identified as increasing with age, such as pseudogene cyc-
lin D2 in the ovary [76], and recent work has indicated
that they may have a role in inflammation [77]. This pro-
vides an exciting new frontier to explore in ageing re-
search, and further work is required to determine whetherany of the pseudogenes identified in this study have func-
tional significance.
Our study is the first to profile lncRNAs in tendon.
LncRNAs are a large and functionally heterogeneous
class of RNAs with a length of more than 200 nucleo-
tides. They have been shown to regulate mRNA tran-
scription, splicing, stability, translation, and epigenetic
modification, providing a complex spectrum of gene
regulatory functions [78], and a number of studies have
identified roles for lncRNAs in ageing [22,79]. In this
study, lncRNAs were shown to be DEGs in ageing tendon,
and 34 showed upregulation in old tendon. In musculo-
skeletal disease, relatively little work interrogates the role
lncRNAs in tissue physiology and disease except for a few
studies in cartilage/OA [80-82] and muscle (reviewed
[83]) and an osteosarcoma study [84]. The lncRNA tran-
scriptome signatures in ageing tendon provide an interest-
ing set of genes for further studies to determine their role
in tendon ageing and disease.
Conclusions
Our study is the first to interrogate tendon by using
RNA-Seq. We demonstrate dynamic alterations in RNA
with age, at numerous genomic levels, which indicate
changes in the regulation of transcriptional networks.
Further extensive follow-up analysis of modulator genes,
splice variants, and non-coding RNAs found in this
study may be useful in understanding tendon ageing.
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Additional file 1: Transcript expression in all samples. A complete list
of significantly expressed genes and DAVID (Database for Annotation,
Visualization and Integrated Discovery) analysis of the expression patterns is
shown in a complete table of all transcript expression as an estimate of
overall abundance of genes in ageing tendon. Reads were used to estimate
transcript expression of all nine samples by using fragments per kilobase of
exon per million fragments mapped (FPKM) in order to identify the most
abundant genes in tendon. Based on the gene annotation file, a gene
contains certain features. The total feature length of a gene is known (GFL).
The count numbers obtained from read alignment for a gene depend on
the real expression level of the gene and its GLF value. Therefore, counts
cannot be used for comparing the expression level among genes. The
sequence depth also influences the count values for given gene expression
level. FPKM corrects for these two effects. FC, fold change; FDR, false
discovery rate; PV, P-value; GFL, Gene feature length SD, standard deviation.
Additional file 2: The entire set of significantly differentially
expressed gene transcripts. Significant differentially expressed genes
have a log2 fold change (FC) ± 1.4 and false discovery rate (FDR)-adjusted
P <0.05. Highest in old (gene names marked in red) are genes more
highly expressed in old tendon compared with young tendon, and
lowest in old (marked in blue) are genes less expressed in old tendon
compared with young tendon.
Additional file 3: The entire list of significantly differentially
expressed gene isoforms. A complete table of significant differentially
expressed isoforms with a log2 fold change ± 1.4 and false discovery
rate-adjusted P <0.05 is shown. FPKM, fragments per kilobase of exon per
million fragments mapped.
Additional file 4: All identified networks and their respective
molecules. Network-eligible molecules were overlaid onto molecular
networks. All identified networks and their respective molecules are
tabulated.
Additional file 5: Associated molecules of the top canonical
pathways. Molecules in the tendon RNA-Seq data set associated with
the top five canonical pathways are shown.
Additional file 6: Skeletal and muscular disorders were the top
diseases associated with the gene set. Disease annotation and
associated P value, activation z-score, and molecules associated with
skeletal and muscular disorders are shown.
Additional file 7: Quantitative real-time polymerase chain reaction
(qRT-PCR) analysis of 12 selected genes reveals good correlation
with RNA-Seq results in an independent cohort. Values for qRT-PCR
are the mean ± standard deviation of relative expression levels normalised
to expression of RPS16. Statistical significance was tested by using Student’s
t test. ACAN, aggrecan; COL1A1, collagen type I alpha 1; COL3A1, collagen
type III, alpha 1; EGF, epidermal growth factor; FC, fold change; IGF1, insulin
growth factor 1; LINC00957, long intergenic non-protein coding RNA 957;
MMP-3, matrix metalloproteinase 3; MMP-16, matrix metalloproteinase 16;
MYF5, myogenic factor 5; MYH1, myosin heavy chain 1; POU3F4, POU class
3 homeobox 4; TGFβ3, transforming growth factor β3; XIST, X inactive
specific transcript.Abbreviations
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